Weihai Lotus Pharmaceuticals Limited which was formed in 1994 is a wholly owned investment of the Lotus Healthcare Group and is located in Weihai City, in the Province of Shandong, China. The Company’s business license allows for the manufacture and sale of Medical Devices, Western as well as Traditional Chinese Medicines in China.
Construction of the cGMP facility provided initially for solid dosage form manufacturing, warehousing, laboratory and office facilities. The site design allows for expansion to progress on a modular or product form basis; thereby progressively increasing manufacturing capability as demand for the products and range of products increase.
The opioid analgesic segment of the China pharmaceutical market is under-served and growing rapidly. Weihai Lotus has been successful in applying for licenses to import certain narcotic APIs; including dihydrocodeine, morphine, oxycodone and hydrocodone. These APIs are used in the manufacture of the company’s pain medications and sold to other appropriately licensed pharmaceutical companies in China.
The facilities in Weihai Lotus are a non-sterile solid dosage form pharmaceutical plant operating to the latest cGMP standards and approved by the Chinese authorities. The site occupies an area of over four acres and includes Pharmaceutical production areas, office buildings,
warehousing and laboratories. The right blend of cost containment, high quality and reliability has been achieved through the selection of locally produced equipment and importing some of the main production equipment. There is space for further expansion into all types of product forms and presentations and sufficient unused land to accommodate other buildings.